Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Merck said in a brief statement that discussions are "advanced" but noted that "critical conditions have yet to be met" ...

Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

SpringWorks Therapeutics shares rose 36% after Reuters reported Germany's Merck KGaA is in advanced talks to buy the company. Shares were trading around $54.66. The stock is up 16% over the last year ...

Merck in Germany was possibly the earliest company to move in this direction. Originating as a pharmacy founded in Darmstadt in 1668, it was in 1827 that Heinrich Emanuel Merck began the ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...